Amgen Inc AMGN
Stock research in plain language · As of Oct 04, 2026 · updated once a week, after the trading week closes
What the company does
Amgen Inc is a mega-cap company in the Healthcare sector (Drug Manufacturers - General), with a market value of $217.9B, based in the USA.
It employs about 31,500 people and has been listed since Jun 17, 1983.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Cheap or expensive? priced in line with its group
Its price-to-earnings (P/E) is 25.3 versus 31.6 for the median of the Healthcare sector in our universe (22 companies) — priced in line with its group.
Revenue is growing 10% versus the same quarter last year.
On analysts' next-year forecasts the multiple drops to 16.7 — they expect higher earnings.
The average analyst price target is 390.94, 3% below the current price (their view, not ours).
The stock sits at 74% of its one-year range (0% = the low, 100% = the high).
The risks
- ⚠️ Net debt is 3.7× shareholders' equity — high leverage.
Strengths
- ✅ Profitable — 24 of every 100 dollars of revenue stays as profit.
- ✅ Generates free cash flow — profit becomes cash in the bank.
- ✅ Pays a dividend (2.4% a year).
What changed this week
Over the past week the stock fell 2.8% (for comparison: S&P 500 -0.2%, sector ETF XLV -2.6%).
This week's news
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy? finance.yahoo.com · 2026-10-04
- AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot seekingalpha.com · 2026-10-03
- Honeywell International (HON) Broke Itself Into Three. Is the Sum Worth More Than the Whole Was? finance.yahoo.com · 2026-10-02
- J&J's Innovative Medicine Segment in Q3: Key Growth Drivers to Watch finance.yahoo.com · 2026-10-02
- 3 Dow Jones Stocks with Exciting Potential finance.yahoo.com · 2026-10-02
- AstraZeneca (AZN) Puts $2 Billion Into Summit Therapeutics (SMMT) for a Cancer Tie-Up finance.yahoo.com · 2026-10-02
A description of facts from the filings and the market — not investment advice or a recommendation. "Cheap" and "expensive" are always relative to the comparison group.